» Articles » PMID: 28620382

Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor Vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma...

Abstract

The irradiated, allogeneic, cellular CSF-470 vaccine plus Bacillus Calmette-Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) is being tested against medium-dose IFN-α2b in stages IIB-III cutaneous melanoma (CM) patients (pts) after surgery in an open, randomized, Phase II/III study. We present the results of the Phase II part of the ongoing CASVAC-0401 study (ClinicalTrials.gov: NCT01729663). Thirty-one pts were randomized to the CSF-470 vaccine ( = 20) or to the IFN-α2b arm ( = 11). During the 2-year treatment, immunized pts should receive 13 vaccinations. On day 1 of each visit, 1.6 × 10 irradiated CSF-470 cells plus 10 colony-forming units BCG plus 100 µg rhGM-CSF were administered intradermally, followed on days 2-4 by 100 µg rhGM-CSF. IFN-α2b pts should receive 10 million units (MU)/day/5 days a week for 4 weeks; then 5 MU thrice weekly for 23 months. Toxicity and quality of life (QOL) were evaluated at each visit. With a mean and a maximum follow-up of 39.4 and 83 months, respectively, a significant benefit in the distant metastasis-free survival (DMFS) for CSF-470 was observed ( = 0.022). Immune monitoring showed an increase in antitumoral cellular and humoral response in vaccinated pts. CSF-470 was well tolerated; 20/20 pts presented grades 1-2 dermic reactions at the vaccination site; 3/20 pts presented grade 3 allergic reactions. Other adverse events (AEs) were grade 1. Pts in the IFN-α2b arm presented grades 2-3 hematological (7/11), hepatic (2/11), and cardiac (1/11) toxicity; AEs in 9/11 pts forced treatment interruptions. QOL was significantly superior in the vaccine arm ( < 0.0001). Our results suggest that CSF-470 vaccine plus BCG plus GM-CSF can significantly prolong, with lower toxicity, the DMFS of high-risk CM pts with respect to medium-dose IFN-α2b. The continuation of a Phase III part of the CASVAC-0401 study is encouraged.

Citing Articles

VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens.

Carri I, Schwab E, Trivino J, von Euw E, Nielsen M, Mordoh J Front Immunol. 2025; 15():1496204.

PMID: 39840067 PMC: 11747570. DOI: 10.3389/fimmu.2024.1496204.


Cancer vaccines: platforms and current progress.

Lei W, Zhou K, Lei Y, Li Q, Zhu H Mol Biomed. 2025; 6(1):3.

PMID: 39789208 PMC: 11717780. DOI: 10.1186/s43556-024-00241-8.


Vaccimel immunization is associated with enhanced response to treatment with anti-PD-1 monoclonal antibodies in cutaneous melanoma patients - a case reports study.

Mordoh J, Schwab E, Bravo A, Aris M, Barrio M Front Immunol. 2024; 15:1354710.

PMID: 38726010 PMC: 11079628. DOI: 10.3389/fimmu.2024.1354710.


HEV-associated dendritic cells are observed in metastatic tumor-draining lymph nodes of cutaneous melanoma patients with longer distant metastasis-free survival after adjuvant immunotherapy.

Bravo A, Aris M, Panouillot M, Porto M, Dieu-Nosjean M, Teillaud J Front Immunol. 2023; 14:1231734.

PMID: 37691949 PMC: 10485604. DOI: 10.3389/fimmu.2023.1231734.


Early contribution of germline and nevi genetic alterations to a rapidly-progressing cutaneous melanoma patient: a case report.

Mordoh A, Trivino Pardo J, Carri I, Barrio M, Mordoh J, Aris M BMC Med Genomics. 2023; 16(1):1.

PMID: 36604730 PMC: 9814418. DOI: 10.1186/s12920-022-01426-2.


References
1.
Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M . Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007; 25(18):2546-53. DOI: 10.1200/JCO.2006.08.5829. View

2.
Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

3.
Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

4.
Anagnostou V, Smith K, Forde P, Niknafs N, Bhattacharya R, White J . Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov. 2016; 7(3):264-276. PMC: 5733805. DOI: 10.1158/2159-8290.CD-16-0828. View

5.
Vogel D, Kooij G, Heijnen P, Breur M, Peferoen L, van der Valk P . GM-CSF promotes migration of human monocytes across the blood brain barrier. Eur J Immunol. 2015; 45(6):1808-19. DOI: 10.1002/eji.201444960. View